NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

CAPR

Capricor Therapeutics Inc

May 08 • 04:00PM ET

6.97

Dollar change +0.08
Percentage change 1.16	%

Healthcare • Biotechnology • USA • NASD

Peers: NVS CRSP SRPT FATE RARE EDIT BLUE SGMO CLLS TVRD

| Held by: VTI IWM XBI VXF IWO VTWO VFMO IWC LABU ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.20	Insider Own	12.16%	Shs Outstand	45.58M	Perf Week	-45.29%
Market Cap	318.37M	Forward P/E	110.88	EPS next Y	0.06	Insider Trans	0.00%	Shs Float	40.12M	Perf Month	-19.89%
Income	-40.47M	PEG	-	EPS next Q	-0.32	Inst Own	38.72%	Short Float	26.60%	Perf Quarter	-51.36%
Sales	22.27M	P/S	14.30	EPS this Y	66.96%	Inst Trans	99.82%	Short Ratio	6.44	Perf Half Y	-62.52%
Book/sh	3.19	P/B	2.18	EPS next Y	116.54%	ROA	-35.31%	Short Interest	10.67M	Perf Year	26.04%
Cash/sh	3.32	P/C	2.10	EPS next 5Y	-	ROE	-48.16%	52W Range	3.52 - 23.40	Perf YTD	-49.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	11.01%	ROI	-27.08%	52W High	-70.21%	Beta	0.98
Dividend TTM	-	Quick Ratio	7.77	Sales past 5Y	345.38%	Gross Margin	93.60%	52W Low	98.01%	ATR (14)	1.23
Dividend Ex-Date	-	Current Ratio	7.77	EPS Y/Y TTM	-37.48%	Oper. Margin	-191.13%	RSI (14)	29.15	Volatility	20.19% 11.29%
Employees	160	Debt/Eq	0.03	Sales Y/Y TTM	-11.55%	Profit Margin	-181.71%	Recom	1.00	Target Price	43.71
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	-544.76%	Payout	-	Rel Volume	2.69	Prev Close	6.89
Sales Surprise	215.98%	EPS Surprise	5.88%	Sales Q/Q	-7.92%	Earnings	May 13 AMC	Avg Volume	1.66M	Price	6.97
SMA20	-35.97%	SMA50	-39.85%	SMA200	-43.85%	Trades		Volume	4,458,612	Change	1.16%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-24	Initiated	Piper Sandler	Overweight	$35
May-17-24	Initiated	Oppenheimer	Outperform	$14
Jan-05-24	Initiated	Cantor Fitzgerald	Overweight	$8
Oct-26-22	Initiated	Ladenburg Thalmann	Buy	$15
Dec-26-18	Downgrade	Maxim Group	Buy → Hold
Jan-26-18	Reiterated	H.C. Wainwright	Buy	$6.50 → $8.60
Sep-15-17	Reiterated	H.C. Wainwright	Buy	$2.15 → $6.50
Feb-13-17	Resumed	Rodman & Renshaw	Buy	$14
Jul-06-16	Resumed	H.C. Wainwright	Buy	$13
Jun-15-16	Initiated	ROTH Capital	Buy

May-06-25 09:15AM	Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 (GlobeNewswire) -29.13%
May-05-25 08:00AM	Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy (GlobeNewswire) -13.15%
Apr-21-25 05:02PM	Capricor Therapeutics Inc (CAPR) Q4 2024 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com) +5.96% +16.53%
08:00AM	OmniAb Announces Two New Appointments to its Board of Directors (Business Wire)
Apr-01-25 09:00AM	Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day (GlobeNewswire)
06:23PM	Loading…
Mar-21-25 06:23PM	Capricor Therapeutics Inc (CAPR) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) -10.45%
Mar-20-25 04:41PM	Is Capricor Therapeutics (CAPR) a Worst High-Risk High-Reward Growth Stock to Buy? (InsiderMonkey) +17.51%
10:21AM	Q4 2024 Capricor Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-19-25 06:57PM	Capricor projects FDA priority review decision for deramiocel by August 2025 (SeekingAlpha) +5.25%
06:56PM	Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript (SeekingAlpha)
05:15PM	Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:17PM	Capricor: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-18-25 09:31AM	Capricor Therapeutics announces long-term data from HOPE-2 OLE study (TipRanks) -9.86%
Mar-17-25 09:25AM	Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
09:00AM	Loading…
Mar-11-25 09:00AM	Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19 (GlobeNewswire)
Mar-10-25 09:13AM	FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment (PR Newswire)
Mar-07-25 09:25AM	Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025 (GlobeNewswire) -5.70%
Mar-06-25 06:20PM	Capricor Therapeutics, Inc. (CAPR): A Bull Case Theory (Insider Monkey) +7.39%
Mar-04-25 11:21AM	Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition (Benzinga)
07:00AM	Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy (GlobeNewswire)
Feb-25-25 12:35PM	Is Capricor Therapeutics, Inc. (CAPR) the Best Small-Cap Growth Stock to Buy Now? (Insider Monkey) +9.34%
Feb-10-25 09:00AM	Capricor Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-16-25 09:55AM	Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade (Zacks)
Jan-02-25 09:15AM	Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire) +8.41%
Dec-02-24 04:15PM	Capricor Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -15.94%
Nov-20-24 09:00AM	Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency (GlobeNewswire)
Nov-16-24 01:28AM	Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025? (Insider Monkey)
Nov-14-24 09:49AM	Q3 2024 Capricor Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +9.34%
Nov-13-24 05:10PM	Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.57%
04:07PM	Loading…
04:07PM	Capricor: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-12-24 09:00AM	Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting (GlobeNewswire) -7.37%
Nov-07-24 09:40AM	Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-05-24 10:00AM	Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline (Zacks)
09:00AM	Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13 (GlobeNewswire)
Oct-18-24 04:01PM	Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +9.07%
Oct-17-24 06:00AM	Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock (GlobeNewswire) -9.85%
Oct-16-24 04:17PM	Capricor Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) -5.05%
Oct-14-24 08:12AM	Capricor touts long-term efficacy of DMD therapy ahead of FDA application (Clinical Trials Arena) +10.19%
Oct-11-24 12:18PM	Capricor Therapeutics Says Duchenne Muscular Dystrophy Candidate Shows Sustained Cardiac, Skeletal Benefits After 3 Years (Benzinga)
09:15AM	Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress (GlobeNewswire)
Oct-09-24 05:17PM	Capricor Therapeutics Inc (CAPR) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) -10.45%
09:15AM	Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Oct-08-24 09:55AM	Does Capricor (CAPR) Have the Potential to Rally 90.16% as Wall Street Analysts Expect? (Zacks) +6.85%
Oct-04-24 09:15AM	Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress (GlobeNewswire) +26.83%
Oct-03-24 05:07AM	Is Capricor Therapeutics, Inc. (CAPR) the Best Russell 2000 Stock to Buy According to Analysts? (Insider Monkey)
Sep-24-24 08:00AM	Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy (GlobeNewswire) +52.43%
07:37AM	Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains? (Zacks)
Sep-23-24 09:25AM	Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024 (GlobeNewswire) +18.22%
Sep-17-24 09:15AM	Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire) +15.19%
09:07AM	EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm (Benzinga)
Sep-06-24 08:30AM	Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences (GlobeNewswire)
Aug-07-24 05:25PM	Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -8.95% +8.99%
04:22PM	Capricor: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-31-24 09:00AM	Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7 (GlobeNewswire)
Jul-01-24 09:00AM	Capricor Therapeutics Set to Join Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
06:12AM	Capricors cell therapy shows three year benefit in DMD patients (Clinical Trials Arena)
Jun-28-24 09:00AM	Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-25-24 10:30AM	CORRECTION: Capricor Therapeutics (GlobeNewswire)
08:30AM	Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-11-24 09:25AM	Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway (GlobeNewswire)
Jun-10-24 09:38AM	Capricor (CAPR) Advances in DMD Therapy With Positive Study Data (Zacks)
Jun-04-24 09:00AM	Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy (GlobeNewswire)
May-17-24 07:59AM	Oppenheimer Initiates Capricor Therapeutics at Outperform Rating (MT Newswires) +9.93%
May-14-24 08:20AM	Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:04AM	Capricor Therapeutics Inc (CAPR) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-13-24 09:54PM	CAPR Stock Earnings: Capricor Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:15PM	Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:17PM	Capricor: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-24 09:15AM	Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting (GlobeNewswire)
May-08-24 09:00AM	Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences (GlobeNewswire)
May-06-24 09:00AM	Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13 (GlobeNewswire)
Apr-24-24 03:21PM	Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug (MT Newswires)
09:00AM	Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy (GlobeNewswire)
Apr-10-24 09:55AM	Wall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Know (Zacks)
Mar-25-24 09:55AM	How Much Upside is Left in Capricor (CAPR)? Wall Street Analysts Think 229.15% (Zacks)
Mar-21-24 08:30AM	Capricor Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-07-24 09:55AM	Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect? (Zacks)
Mar-06-24 08:30AM	Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (GlobeNewswire)
Mar-02-24 08:17AM	Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 06:06AM	Q4 2023 Capricor Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +8.69%
Feb-29-24 04:42PM	Capricor Therapeutics Inc (CAPR) Reports Encouraging Year-End Financials and Advances in DMD Therapy (GuruFocus.com)
04:35PM	Capricor: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-27-24 08:30AM	Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy (GlobeNewswire) +9.60%
Feb-22-24 08:30AM	Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29 (GlobeNewswire)
Feb-20-24 08:30AM	Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization (GlobeNewswire) +6.37%
Jan-24-24 09:15AM	Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2 (GlobeNewswire)
Dec-11-23 09:00AM	Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis (GlobeNewswire)
Nov-16-23 08:28AM	Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 04:30PM	Capricor: Q3 Earnings Snapshot (Associated Press Finance) +5.99% +6.64%
04:05PM	Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-23 09:15AM	Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14 (GlobeNewswire)
Nov-02-23 10:00AM	Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline (Zacks)
Oct-25-23 09:35AM	After Plunging -52.01% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR) (Zacks)
Oct-24-23 09:35AM	After Plunging -50.99% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR) (Zacks)
Oct-19-23 04:01PM	Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program (GlobeNewswire)

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy ("DMD"), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Marban Linda	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Option Exercise	1.39	25,000	34,750	223,604	Mar 05 05:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Mar 03 '25	Option Exercise	1.39	2,500	3,475	8,223	Mar 04 07:00 PM
Litvack Frank	Director	Mar 03 '25	Option Exercise	1.39	25,000	34,750	132,382	Mar 04 07:00 PM
DUNBAR GEORGE W JR	Director	Mar 03 '25	Option Exercise	1.39	750	1,042	11,306	Mar 04 07:00 PM
COLLIER EARL M JR	Director	Feb 27 '25	Option Exercise	1.39	750	1,042	57,606	Feb 28 07:30 PM
Krasney Karen	EVP, GENERAL COUNSEL	Dec 13 '24	Option Exercise	1.39	8,000	11,120	28,047	Dec 16 09:25 AM
Litvack Frank	Director	Dec 03 '24	Option Exercise	1.10	20,391	22,430	46,278	Dec 04 08:00 PM
Nippon Shinyaku Co Ltd	10% Owner	Sep 20 '24	Buy	5.36	2,798,507	14,999,998	7,090,351	Sep 24 04:01 PM
Musket David B	Director	Aug 07 '24	Option Exercise	1.39	34,000	47,260	81,692	Aug 09 09:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CAPR

Capricor Therapeutics Inc

Upgrade your FINVIZ experience